![Dr. Cerchietti Receives Doris Duke Clinical Scientist Award for Study of B-Cell Lymphoma | Weill Department of Medicine Dr. Cerchietti Receives Doris Duke Clinical Scientist Award for Study of B-Cell Lymphoma | Weill Department of Medicine](https://medicine.weill.cornell.edu/sites/default/files/styles/panopoly_image_quarter/public/profile_images/cerchietti-leandro.jpg?itok=4c2d9BmY)
Dr. Cerchietti Receives Doris Duke Clinical Scientist Award for Study of B-Cell Lymphoma | Weill Department of Medicine
![Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL) - ScienceDirect Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497118692675-gr1.jpg)
Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL) - ScienceDirect
Weill Cornell Lymphoma Program - Dr. Rossella Marullo of Dr. Leandro Cerchietti's Lab was selected to receive an American Society of Hematology Fellow to Faculty Scholar Award in basic/translational research. Please join
![PDF) Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas PDF) Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas](https://i1.rgstatic.net/publication/51052731_Inhibition_of_Anaplastic_Lymphoma_Kinase_ALK_Activity_Provides_a_Therapeutic_Approach_for_CLTC-ALK-Positive_Human_Diffuse_Large_B_Cell_Lymphomas/links/0deec51e95a707cda0000000/largepreview.png)